



Correction to: Targeted Anti-IL-5 Therapies and Future Therapeutics for Hypereosinophilic Syndrome and Rare Eosinophilic Conditions

Aasha Harish¹ · Stanley A. Schwartz¹

Published online: 18 March 2020

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Correction to: Clinical Reviews in Allergy & Immunology
<https://doi.org/10.1007/s12016-019-08775-4>

The original version of this article unfortunately contained a mistake in the first sentence of the fifth paragraph of the “Conclusion” section. The corrected text reads “Dexramipexole, an investigational drug initially developed for the treatment of amyotrophic lateral sclerosis, has been shown to cause sustained eosinopenia”. Additionally, in that same paragraph, the units used to measure eosinophil counts should read “ μL^{-1} ”.

The original article has been corrected.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The online version of the original article can be found at <https://doi.org/10.1007/s12016-019-08775-4>

✉ Aasha Harish
aashahar@buffalo.edu

¹ Division of Allergy and Immunology, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, 1020 Youngs Road, Williamsville, NY 14221, USA